Race- and ethnicity-based disparities in uterine cancer survival vary by geographic locations across the United States.

The Wee1 inhibitor adavosertib shows activity in recurrent uterine serous carcinoma, but the drug’s tolerability remains a ...

Endometrial cancer is the most common gynecological cancer in highly-developed countries, most often affecting women after ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Uterine leiomyosarcoma may be rare, but awareness can save lives. If you or someone you love is experiencing persistent or ...

According to the NHS, symptoms of bowel cancer to look out for include ... anyone with a womb can be diagnosed with uterine cancer. The most obvious symptom is abnormal bleeding from the vagina, but ...

Some symptoms, such as a lump in the breast or ... National Cancer Institute. Uterine cancer-patient version. Sung S, Carlson K, Abramovitz A. Postmenopausal bleeding. In: StatPearls.

Canada is among countries that have made it a goal to eliminate cervical cancer by or before 2040, but between 2015 and 2019 ...

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial.

In both studies, the PD-1 inhibitors plus chemotherapy were compared to chemo plus placebo and showed they were more effective at extending progression-free survival (PFS). In RUBY, Jemperli ...